Soluble suppression of tumorigenicity 2 associated with microvascular obstruction in patients with ST-segment elevation myocardial infarction

Xinjia Du,Jiahua Liu,Jingfang Zhou,Yanfei Ren,Nauman Gul,Lei Chen,Yuan Lu
DOI: https://doi.org/10.1186/s12872-024-04364-2
IF: 2.174
2024-12-01
BMC Cardiovascular Disorders
Abstract:Microvascular obstruction (MVO) develops in approximately 50% of patients with ST-segment elevation myocardial infarction (STEMI) after undergoing percutaneous coronary intervention (PCI). MVO is strongly linked to inflammation, myocardial fibrosis, and adverse clinical outcomes. Soluble suppression of tumorigenicity 2 (sST2) serves as a biomarker for inflammation and myocardial fibrosis. Yet, the correlation between sST2 and MVO in STEMI patients has not been fully elucidated. This study attempts to evaluate the association between sST2 levels and MVO in STEMI patients following pPCI.
cardiac & cardiovascular systems
What problem does this paper attempt to address?